Immunologic Factors: all 3,292 studies that test it

Page 16 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00064038Phase 3Results posted
• Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00062010Phase 2Results posted
• Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's MacroglobulinemiaTerminatedNCT00060346Phase 2Results posted
• Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedNCT00058422Phase 2Results posted
• CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00056160Phase 3Results posted
• Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
• S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell LymphomaCompletedNCT00041132Phase 2Results posted
• Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With LymphomaCompletedNCT00039195Phase 2Results posted
• Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's LeukemiaCompletedNCT00039130Phase 2Results posted
• Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesCompletedNCT00038857Phase 2Results posted
• Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic VasculitisCompletedNCT00029107Phase 2Results posted
• Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT00026312Phase 3Results posted
• Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
• S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00006721Phase 3Results posted
• Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's LymphomaTerminatedNCT00006478Phase 2Results posted
• EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCompletedNCT00006436Phase 2Results posted
• Sirolimus and Thymoglobulin to Prevent Kidney Transplant RejectionCompletedNCT00006178Phase 2Results posted
• Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaCompletedNCT00005937Phase 2Results posted
• Rituximab in Treating Patients With Hodgkin's LymphomaCompletedNCT00003820Phase 2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaCompletedNCT00003659Phase 2Results posted
• Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney CancerCompletedNCT00003656Phase 2Results posted
• Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerCompletedNCT00003199Phase 2Results posted
• Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisCompletedNCT00001586Phase 2Results posted
• Treatment and Natural History Study of Lymphomatoid GranulomatosisCompletedNCT00001379Phase 2Results posted
• Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00001337Phase 2Results posted
• Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)Active, not recruitingNCT07735039Not applicable
• Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male SubjectsCompletedNCT07694011Phase 1
• Adjuvant Therapy of Skin Melanoma With Alpha Interferon and NaderinCompletedNCT07671495Phase 2
• A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingNCT07597668Phase 1
• Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.CompletedNCT07532707Not applicable
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingNCT07483450Phase 4
• Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaActive, not recruitingNCT07247383Phase 2
• Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07193953Phase 1
• Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCCCompletedNCT07184424Not applicable
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4
• Rituximab for the Treatment of New-onset AChR-Myasthenia GravisActive, not recruitingNCT07071246Not applicable
• Rituximab and Targeted Nursing for Pediatric Nephrotic SyndromeCompletedNCT07049172Not applicable
• Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity PneumonitisCompletedNCT07035561Phase 2
• A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaWithdrawnNCT07030699Phase 2
• A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection ConditionsCompletedNCT07025577Phase 1
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT06847724Phase 3
• Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy ParticipantsCompletedNCT06753955Phase 1
• Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedNCT06738368Phase 2
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Active, not recruitingNCT06685757Phase 3
• IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisSuspendedNCT06677710Phase 1
• Pomalidomide as an Immune-enhancing Agent for the Control of HIVActive, not recruitingNCT06660498Phase 1/2
• Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active, not recruitingNCT06647732Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingNCT06541665Phase 1
• The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And EpigeneticsActive, not recruitingNCT06534450Phase 3
• GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
• Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
• Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
• Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaActive, not recruitingNCT06334991Phase 1
• Rituximab in Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT06325943Phase 3
• RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)CompletedNCT06305793Phase 2
• Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Active, not recruitingNCT06284122Phase 3
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
• A Study of Glofitamab and Lenalidomide in People With Mantle Cell LymphomaActive, not recruitingNCT06192888Phase 1
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
• Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous GoutCompletedNCT06186219Phase 1
• Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid ArthritisActive, not recruitingNCT06175338Phase 1
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaActive, not recruitingNCT06112847Phase 2
• A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1
• Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCWithdrawnNCT06064279Phase 1/2
• Post Marketing Surveillance of Diphtheria Antitoxin (DAT)CompletedNCT06053853Phase 4
• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedNCT06046248Phase 2
• MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
• Early and Late Prognosis in Patients With Guillain-Barre SyndromeStatus unknownNCT06041451Phase 4
• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaWithdrawnNCT06015750Phase 4
• Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority TrialActive, not recruitingNCT05999604Phase 3
• Rituxmab Versus IL-6 in Treating ILDCompletedNCT05963048Phase 2/3
• A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
• A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaActive, not recruitingNCT05950165Phase 1/2
• Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
• An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
• Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic SyndromeActive, not recruitingNCT05914155Phase 3
• SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
• A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune TherapyActive, not recruitingNCT05877040Phase 2
• Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
• Add-on Intravenous Immunoglobulins in Early MyositisActive, not recruitingNCT05832034Phase 2/3
• A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA NephropathyStatus unknownNCT05824390Phase 4
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
• Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
• Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived InfectionsStatus unknownNCT05799716Phase 4
• Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPActive, not recruitingNCT05798156Phase 2
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
• Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous NephropathyStatus unknownNCT05782933Not applicable
• R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
• First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228Active, not recruitingNCT05737628Phase 1
• Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
• A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT05683171Phase 1/2
• Biomarker Validation Following Sargramostim Treatment in Parkinson's DiseaseCompletedNCT05677633Phase 1

← Immunologic Factors overview